Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer
Alec Paschalis(Royal Marsden NHS Foundation Trust), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Semini Sumanasuriya(Institute of Cancer Research), George Seed(Institute of Cancer Research), Pasquale Rescigno(Royal Marsden NHS Foundation Trust), Wei Yuan(Chinese Academy of Medical Sciences & Peking Union Medical College), Bora Gürel(Institute of Cancer Research), Antje Neeb(Institute of Cancer Research), David Dolling(Institute of Cancer Research), Nina Tunariu(Leicester Royal Infirmary), Beshara Sheehan(Institute of Cancer Research), Adam Sharp(Institute of Cancer Research), Ana Ferreira(Institute of Cancer Research), Daniel Nava Rodrigues(Royal Marsden NHS Foundation Trust), Jon Welti(Institute of Cancer Research), Suzanne Carreira(Institute of Cancer Research), Diletta Bianchini(Royal Marsden NHS Foundation Trust), Ruth Riisnaes(Institute of Cancer Research), Wim J.G. Oyen(Institute of Cancer Research), Maryou B. Lambros(Institute of Cancer Research), Cláudia Bertan(Institute of Cancer Research)
Cited by 464
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k